Published: Thursday, July 3, 2025 · 12:30 AM | Updated: Thursday, July 3, 2025 · 12:30 AM
📊 289 views
Zimmer Biomet Holdings, Inc. (ZBH, Financial) has entered into two significant revolving credit agreements, enhancing its financial flexibility and supporting its corporate strategy. The agreements, effective June 27, 2025, include a Five-Year Revolving Credit Agreement and a 364-Day Revolving Credit Agreement, both facilitated by JPMorgan Chase Bank, N.A.
The Five-Year Revolving Credit Agreement provides Zimmer Biomet with a $1.5 billion unsecured revolving facility, maturing on June 27, 2030. This agreement includes an option for two one-year extensions, subject to lender consent, and an uncommitted incremental feature allowing for an increase of up to $500 million. The funds from this facility will be utilized for general corporate purposes, with interest rates based on either an adjusted Term secured overnight financing rate (SOFR) or an alternate base rate, plus a margin linked to the company’s senior unsecured long-term debt credit rating.
Additionally, Zimmer Biomet has secured a 364-Day Revolving Credit Agreement, offering a $1.0 billion unsecured revolving facility, maturing on June 26, 2026. Similar to the Five-Year Agreement, this facility will support general corporate purposes and bears interest at floating rates determined by the company’s credit rating.
Both credit agreements include customary covenants and events of default, with a requirement for Zimmer Biomet to maintain a consolidated indebtedness to consolidated EBITDA ratio of no greater than 4.5 to 1.0, adjustable to 5.0 to 1.0 in the event of a qualified material acquisition.
On the same date, Zimmer Biomet borrowed $50 million under the new Five-Year Credit Agreement, replacing a portion of the borrowings from the previous five-year credit agreement, which was terminated. The transition also included the transfer of existing letters of credit to the new agreement.
These strategic financial moves underscore Zimmer Biomet’s commitment to maintaining robust financial health and operational flexibility, positioning the company for continued growth and stability in the competitive medical device industry.
Should you invest in Zimmer Biomet Holdings Inc (ZBH, Financial) right now? Before you do it, it’s important to understand the business profitability and stock valuations, and find out what the warning signs are about. See the in-depth Zimmer Biomet Holdings Inc (ZBH) stock research here.
MORE IN INSIDE INVESTMENT NEWS
Nike stock: A Portfolio Warning After Disappointing Quarter
Published: Tuesday, June 30, 2026 · 11:47 PM
AeroVironment: Alpha Generation in the Drone Defense Market
Published: Monday, June 29, 2026 · 10:17 PM
